Menu
Search
|

Menu

Close
X

Minerva Neurosciences Inc NERV.OQ (NASDAQ Stock Exchange Global Market)

6.49 USD
-- (--)
As of Jul 18
Previous Close 6.49
Open --
Volume --
3m Avg Volume 140,811
Today’s High --
Today’s Low --
52 Week High 12.95
52 Week Low 4.10
Shares Outstanding (mil) 39.03
Market Capitalization (mil) 253.28
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-0.406
FY18
-1.293
FY17
-1.081
FY16
-0.985
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.10
Price to Sales (TTM)
vs sector
--
7.99
Price to Book (MRQ)
vs sector
3.27
4.39
Price to Cash Flow (TTM)
vs sector
--
24.00
Total Debt to Equity (MRQ)
vs sector
0.00
17.94
LT Debt to Equity (MRQ)
vs sector
0.00
12.82
Return on Investment (TTM)
vs sector
-37.02
12.64
Return on Equity (TTM)
vs sector
-53.93
17.18

EXECUTIVE LEADERSHIP

Remy Luthringer
Executive Chairman of the Board, Chief Executive Officer, Since 2018
Salary: $525,000.00
Bonus: $196,875.00
Richard Russell
President, Since 2017
Salary: $475,000.00
Bonus: $278,125.00
Geoffrey Race
Executive Vice President, Chief Financial Officer and Chief Business Officer, Since 2016
Salary: $397,000.00
Bonus: $148,875.00
Joseph Reilly
Chief Operating Officer, Senior Vice President, Since 2015
Salary: --
Bonus: --
Frederick Ahlholm
Senior Vice President, Chief Accounting Officer, Since 2015
Salary: $154,583.00
Bonus: $75,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1601 Trapelo Rd Ste 286
WALTHAM   MA   02451-7337

Phone: +1617.6007373

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson's disease. MIN-101 is a compound that blocks serotonin receptors and sigma receptors, two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-hydroxytryptamine type 1A (5-HT1A). MIN-202 is a selective orexin 2 receptor antagonist. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein, for the treatment of Parkinson's disease.

SPONSORED STORIES